MIRM - Mirum Pharmaceuticals, Inc.

QQQ $ 442.22 $ 1.06 (0.24 %)

DIA $ 394.87 $ 0.87 (0.22 %)

SPY $ 520.84 $ -0.68 (-0.13 %)

TLT $ 90.06 $ -0.57 (-0.63 %)

GLD $ 219.26 $ -0.52 (-0.24 %)

Previous Close

$ 25.83

Open

$ 26.17

Bid

$ 24.93 x 100

Ask

$ 0.00 x 0

Day's Range

$ 24.74 - $ 26.17

52 Week Range

$ 23.14 - $ 35.56

Volume

631,766

Average Volume

Market Cap

1.21B

Beta (5Y Monthly)

$ 0.99

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-08-2024	03-31-2024	10-Q
2	03-15-2024	12-31-2023	10-K
3	11-02-2023	09-30-2023	10-Q
4	08-07-2023	06-30-2023	10-Q
5	05-04-2023	03-31-2023	10-Q
6	03-08-2023	12-31-2022	10-K
7	11-09-2022	09-30-2022	10-Q
8	08-04-2022	06-30-2022	10-Q
9	05-05-2022	03-31-2022	10-Q
10	03-09-2022	12-31-2021	10-K
11	11-15-2021	09-30-2021	10-Q
12	08-05-2021	06-30-2021	10-Q
13	05-06-2021	03-31-2021	10-Q
14	03-09-2021	12-31-2020	10-K
15	11-12-2020	09-30-2020	10-Q
16	08-06-2020	06-30-2020	10-Q
17	05-07-2020	03-31-2020	10-Q
18	03-12-2020	12-31-2019	10-K
19	11-06-2019	09-30-2019	10-Q
20	08-28-2019	06-30-2019	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Morgan Stanley Maintains Overweight on Mir...
05/10/2024 15:43:43

Morgan Stanley analyst Michael Ulz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and lowers the price targ...

JMP Securities Maintains Market Outperform...
05/09/2024 18:39:28

JMP Securities analyst Jonathan Wolleben maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Market Outperform and lowers t...

Citigroup Maintains Buy on Mirum Pharmaceu...
05/09/2024 17:45:38

Citigroup analyst David Lebovitz maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target from $...

Cantor Fitzgerald Reiterates Overweight on...
05/09/2024 14:25:49

Cantor Fitzgerald analyst Josh Schimmer reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and maintains $40 p...

Analyst Ratings For Mirum Pharmaceuticals
05/09/2024 12:01:07

HC Wainwright & Co. Reiterates Buy on Miru...
05/09/2024 10:38:19

HC Wainwright & Co. analyst Ed Arce reiterates Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and maintains $58 price ta...

Mirum Pharmaceuticals Q1 2024 GAAP EPS $(0...
05/08/2024 20:44:55

Mirum Pharmaceuticals (NASDAQ:MIRM) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate ...

Mirum Announces Publication Of Phase 3 MAR...
05/07/2024 12:30:41

- Data demonstrate significant benefit across broadest range of genetic PFIC types ever studied- Significant improvements obser...

Analyst Ratings For Mirum Pharmaceuticals
04/17/2024 13:00:19

Stifel Initiates Coverage On Mirum Pharmac...
04/17/2024 11:14:32

Stifel analyst Dae Gon Ha initiates coverage on Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy rating and announces Price Ta...

HC Wainwright & Co. Maintains Buy on Mirum...
04/02/2024 15:37:21

HC Wainwright & Co. analyst Ed Arce maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and maintains $58 price tar...

Mirum Pharmaceuticals' LIVMARLI Receives R...
04/02/2024 12:37:58

- Positive HTA recommendation for reimbursement signifies an important milestone towards public funding to treat eligible patie...

$5M Bet On Snowflake? Check Out These 4 St...
03/28/2024 12:33:08

Although U.S. stocks closed higher on Wednesday, there were a few notable insider trades.

Cracking The Code: Understanding Analyst R...
03/18/2024 19:00:23

Leerink Partners Maintains Outperform on M...
03/18/2024 18:10:52

Leerink Partners analyst Mani Foroohar maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and lowers the price ...

fda-approves-mirums-livmarli-for-liver-disease-in-kids-as-young-as-5-years-analyst-bullish-on-label-expansion-strategy

FDA Approves Mirum's Livmarli For Liver Di...
03/14/2024 19:40:59

FDA approves Livmarli by Mirum Pharmaceuticals for cholestatic pruritus in PFIC patients ≥5 years old. Data from Phase 3 MARCH ...

HC Wainwright & Co. Maintains Buy on Mirum...
03/14/2024 10:45:18

HC Wainwright & Co. analyst Ed Arce maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and raises the price target...

Mirum Pharmaceuticals Says LIVMARLI Receiv...
03/13/2024 22:01:40

FDA has approved LIVMARLI (maralixibat) oral solution for the treatment of cholestatic pruritus in patients five years of age a...

Cantor Fitzgerald Maintains Overweight on ...
03/04/2024 15:27:03

Cantor Fitzgerald analyst Josh Schimmer maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Overweight and raises the price...

HC Wainwright & Co. Maintains Buy on Mirum...
02/29/2024 20:07:57

HC Wainwright & Co. analyst Ed Arce maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Buy and lowers the price target...